Sharath has over 28 years of drug-discovery experience; all of it in the San Francisco Bay Area biotech hub. He has participated in the discovery of numerous New Chemical Entities (NCE), including the marketed products Yupelri®, Vibativ® and several others in different stages of clinical development. Prior to joining Recursion, Sharath spent 19 years at Theravance Biopharma where he was Senior Vice President, Research. Before Theravance, Sharath spent 9 years at Syntex Corporation, later acquired by Roche Holdings, Ltd.
Sharath obtained his Ph.D in Pharmacology from the University of Houston and his B.Pharm and M.Pharm from the University of Mumbai. Sharath loves reading, the outdoors and collecting antique medicine containers.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.